MWM
VKTX icon

MBE Wealth Management’s Viking Therapeutics VKTX Stock Holding History

MBE Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,088
Closed -$5K – 500
2020
Q1 		$5K Buy
+1,088
New +$6.69K ﹤0.01% 382

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

MBE Wealth Management's VKTX Position: Q2 2020 in Review

MBE Wealth Management sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 1,088 shares — an estimated $5K sold.

MBE Wealth Management first reported a position in VKTX in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

  • MBE Wealth Management reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
  • MBE Wealth Management sold 1,088 Viking Therapeutics shares in Q2 2020, an estimated $5K.
  • MBE Wealth Management first reported a position in Viking Therapeutics in Q1 2020 and held it in 1 quarter.
  • MBE Wealth Management's Viking Therapeutics position peaked at $5K in Q1 2020.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on MBE Wealth Management's 13F filing for Q2 2020, filed 14 Aug 2020.